| LTX-109 (lytixar) |
Skin infection caused by gram-negative bacteria and gram-positive
bacteria such as methicillin resistant and sensitive S.
aureus nasal carriage |
Topical |
Disrupt bacteria via permeabilization of membrane |
Phase 2 |
Lytix Biopharma |
| Omiganan (MB1-226, MX-594AN) |
Anti-inflammatory |
Topical |
Catheter-associated infections |
Phase 3 (completed) |
Migenix |
| XF-73 |
Infections due to Staphylococcus during surgeries,
nasal carriage |
Topical |
Disrupt bacteria via permeabilization of membrane |
Phase 2 (recruiting) |
Destiny Pharma |
| Surotomycin |
Diarrhea due to C. difficile
|
Oral |
Depolaries bacterial membrane |
Phase 3 (completed) |
Cubist Pharmaceuticals, Merck and Co |
| P2TA |
Infections caused by necrotizing soft tissues |
Intravenous |
Immunomodulation |
Phase 3 |
Atox Bio |
| Opebacan |
Wound, burn, meningococcal infections |
Intravenous |
Disrupt bacterial membrane via permeabilization |
Phase 2 |
Xoma |
| DPK 060 |
Infections due to eczematous lesions |
Tropical |
- |
Phase 2 |
DermaGen AB |
| Murepavadin (POL 7080) |
Lower respiratory infections due to P. aeruginosa and
ventilator-associated Pneumonia |
Intravenous |
Disrupt LPS and transport protein D |
Phase 3 |
Polyphor |
| PMX-30063 (brilacidin) |
Bacterial skin infections |
Intravenous or tropical |
Disrupt bacterial membrane via permeabilization |
Phase 2 |
Innovation pharmaceuticals |
| Histatin-1 and -3, P-113 (histamin derivatives) |
Chronic infections due to P. aeruginosa, gingivitis,
and periodontal diseases |
Tropical |
Generation of ROS |
Phase 1,2,3 |
Demgen |
| Human Lactoferrin derived peptide (hLF1-11) |
Infectious diseases due to gram-negative bacteria |
Intravenous |
Disrupt cells by binding to DNA |
Phase 1 (completed) |
AM-Pharma |
| C15G2, Novispirin analogue |
Dental caries infections due to Streptococcus
mutans |
Oral |
Selective disruption of membrane and intracellular targets |
Phase 2 |
|
| Brilacidin (PMX-30063), defensin mimetic |
Broad spectrum antibacterial therapy |
Oral |
Disruption of bacterial membrane |
Phase 2 |
|
| Opebacan (Rbp121, neuprex) |
LPS/endotoxin of gram-negative bacteria |
Intravenous |
Damage to bacterial membrane |
Phase 2 |
|
| XOMA-629 (XMP-629) |
LPS/endotoxins of gram-negative bacteria |
Tropical |
Damage to bacterial membrane |
Phase 2 |
|
| Novarifyn (NP432) |
Bacterial infection |
Tropical |
Disruption of bacterial membrane |
Phase 1 |
|
| AMP PL-18 |
Bacterial vaginosis and mixed vaginitis |
Tropical |
- |
Phase 1 |
Protelight Pharmaceuticals Australia PTY LTD |
